The aim of our study is to assess the efficacy and safety of early use of m TOR inhibitors-based immunosuppression compared with standard immunosuppression in heart transplantation recipients. We reviewed eight random...The aim of our study is to assess the efficacy and safety of early use of m TOR inhibitors-based immunosuppression compared with standard immunosuppression in heart transplantation recipients. We reviewed eight randomized controlled trials identified from Medline/Pub Med, Embase, web of science, Transplant Library and Cochrane Library to evaluate the effects of m TOR inhibitors therapy on outcomes of biopsy-proven acute rejection,acute rejection associated with hemodynamic compromise, death, cytomegalovirus infection, post-transplant malignancy, cardiac allograft vasculopathy, maximal intimal thickness and renal function. Meta-analysis including 2066recipients showed a significantly lower incidence of biopsy-proven acute rejection, cytomegalovirus infection, cardiac allograft vasculopathy and decreased maximal intimal thickness change. In conclusion, our meta-analysis suggested that early use of m TOR inhibitors-based immunosuppression were more effective and safer compared with standard immunosuppression in heart transplant recipients, especially in reducing acute rejection, cytomegalovirus infection, cardiacallograft vasculopathy and preserving renal function when combined with reduced calcineurin inhibitors.展开更多
基金supported in part by research grants from the National Key Research and Development Program of China(NO.2018YFA0108700)NSFC Projects of International Cooperation and Exchanges(81720108004)+6 种基金National Natural Science Foundation of China(NO.81974019)Guangdong Provincial Special Support Program for Prominent Talents(2021JC06Y656)Science and Technology Planning Project of Guangdong Province(NO.2020B1111170011,NO.2022B1212010010)Guangdong special funds for science and technology innovation strategy,China(Stability support for scientific research institutions affiliated to Guangdong Province-GDCI 2021)Guangzhou Science and Technology Plan Project(NO.202201000006)the Special Project of Dengfeng Program of Guangdong Provincial Peoples Hospital(NO.DFJH201812,NO.KJ012019119,NO.KJ012019423)the Postdoctoral Sustentation Fund of Guangdong Provincial People’s Hospital(NO.BY012020015)
文摘The aim of our study is to assess the efficacy and safety of early use of m TOR inhibitors-based immunosuppression compared with standard immunosuppression in heart transplantation recipients. We reviewed eight randomized controlled trials identified from Medline/Pub Med, Embase, web of science, Transplant Library and Cochrane Library to evaluate the effects of m TOR inhibitors therapy on outcomes of biopsy-proven acute rejection,acute rejection associated with hemodynamic compromise, death, cytomegalovirus infection, post-transplant malignancy, cardiac allograft vasculopathy, maximal intimal thickness and renal function. Meta-analysis including 2066recipients showed a significantly lower incidence of biopsy-proven acute rejection, cytomegalovirus infection, cardiac allograft vasculopathy and decreased maximal intimal thickness change. In conclusion, our meta-analysis suggested that early use of m TOR inhibitors-based immunosuppression were more effective and safer compared with standard immunosuppression in heart transplant recipients, especially in reducing acute rejection, cytomegalovirus infection, cardiacallograft vasculopathy and preserving renal function when combined with reduced calcineurin inhibitors.
